[1] van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med, 2023; 388, 9−21.
[2] Jönsson L, Wimo A, Handels R, et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer’s disease: an EADC-EC viewpoint. Lancet Reg Health Eur, 2023; 29, 100657.
[3] Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis, 2023; 10, 362−77.
[4] Varadharajan A, Davis AD, Ghosh A, et al. Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs. J Neurosci Rural Pract, 2023; 14, 566−73.
[5] Dhruva SS, Kesselheim AS, Woloshin S, et al. Physician perspectives on the food and drug administration’s decision to grant accelerated approval to aducanumab for Alzheimer’s disease. Clin Pharmacol Ther, 2023; 114, 614−7.
[6] Molchan S, Fugh-Berman A. Are new Alzheimer drugs better than older drugs? JAMA Intern Med, 2023; 183, 902−3.
[7] Qiao Y, Chi YW, Zhang QY, et al. Safety and efficacy of lecanemab for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci, 2023; 15, 1169499.
[8] Lacorte E, Ancidoni A, Zaccaria V, et al. Safety and efficacy of monoclonal antibodies for Alzheimer’s disease: a systematic review and meta-analysis of published and unpublished clinical trials. J Alzheimers Dis, 2022; 87, 101−29.
[9] Wright AC, Lin GA, Whittington MD, et al. The effectiveness and value of lecanemab for early Alzheimer disease: a summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum. J Manag Care Spec Pharm, 2023; 29, 1078−83.
[10] Li X Q, Ji M, Zhang H M, et al. Non-drug therapies for Alzheimer’s disease: a review. Neurol Ther, 2023; 12, 39−72.